Related Experiment Video
Updated: Jun 13, 2025
An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues
Published on: April 5, 2018
Expression landscape of epigenetic genes in human hepatocellular carcinoma
Borja Castelló-Uribe1, Amaya López-Pascual1,2, Jasmin Elurbide1,3
1Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
Abstract:
Hepatocellular carcinoma (HCC) is the most common primary liver tumor, often arising in the context of chronic liver disease. Despite recent advances in systemic therapies, including the use of immune checkpoint inhibitors (ICIs), clinical outcomes remain suboptimal, with many patients exhibiting primary or acquired resistance. Accumulating evidence indicates that the dysregulation of epigenetic mechanisms contributes to HCC development, and may also play a crucial role in shaping the tumor immune microenvironment, influencing responses to treatments. In this study, we analyzed the expression profiles of a comprehensive set of epigenetic regulators across publicly available transcriptomic datasets of HCC and non-tumoral liver tissues. Our findings reveal a consistent dysregulation of key epigenetic modifiers, particularly those involved in DNA methylation and histone modification. Furthermore, our analysis underscores the need for a deeper understanding of the epigenetic landscape of HCC, as specific epigenetic patterns are directly associated with disease development, the major mutational, immune, and transcriptional subclasses of HCC, and patient clinical outcomes. Our study provides a foundation for integrating epigenetic biomarkers into patient stratification and therapeutic decision-making. A more comprehensive analysis of epigenetic alterations could pave the way for novel predictive markers and combination strategies that could enhance the efficacy of ICIs in HCC.
Insights
Epigenetic regulators are altered in hepatocellular carcinoma (HCC), impacting tumor development and immune response. Understanding these epigenetic changes is key to improving HCC treatment strategies and patient outcomes.
Area of Science:
- Oncology
- Epigenetics
- Immunology
Background:
- Hepatocellular carcinoma (HCC) is a primary liver tumor frequently linked to chronic liver disease.
- Current systemic therapies, including immune checkpoint inhibitors (ICIs), show limited efficacy due to resistance.
- Epigenetic dysregulation is implicated in HCC development and influences the tumor immune microenvironment and treatment response.
Purpose of the Study:
- To analyze the expression of epigenetic regulators in HCC.
- To investigate the association between epigenetic patterns and HCC subclasses, immune microenvironment, and clinical outcomes.
- To explore the potential of epigenetic biomarkers for patient stratification and enhancing ICI efficacy.
Main Methods:
- Analysis of comprehensive epigenetic regulator expression profiles.
- Utilized publicly available transcriptomic datasets of HCC and non-tumoral liver tissues.
- Correlated epigenetic patterns with HCC development, mutational, immune, and transcriptional subclasses, and patient outcomes.
Main Results:
- Consistent dysregulation of key epigenetic modifiers, including DNA methylation and histone modification enzymes, was observed in HCC.
- Specific epigenetic patterns were directly associated with HCC subclasses and patient clinical outcomes.
- The study identified a foundation for integrating epigenetic biomarkers into HCC management.
Conclusions:
- Epigenetic alterations are crucial in HCC pathogenesis and immune modulation.
- A deeper understanding of the HCC epigenetic landscape is necessary for therapeutic advancements.
- Epigenetic biomarkers may improve patient stratification and enhance the efficacy of immune checkpoint inhibitors in HCC.
Related Concept Videos
01:37Epigenetic Regulation
X-chromosome...
01:58Cell Specific Gene Expression
02:32Histone Modification
03:18Non-LTR Retrotransposons